SBIR/STTR Research Award

A MINIMALLY INVASIVE DEVICE FOR ENDOMETRIAL IMAGING

Award identifier f20ccf335a259dc6caa0f817320c790730b5469f76771f56d6912a42b527e434Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$344,738

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INFINITE BIOMEDICAL TECHNOLOGIES, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
J795AYLMUM83
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant):Endometrial carcinoma is the most common gynecological cancer in the United States, affecting over 1 in 50 women during her lifetime. Image-guided biopsy using the hysteroscope is significantly more sensitive than blind endometrial biopsy (EMB) for diagnosis of endometrial pathology. However, the majority of gynecologists do not use hysteroscopy, largely due to a steep learning curve. Therefore, we propose development of an automated minimally invasive imaging device which is as easy to use as an EMB. The device uses a 3mm rigid rod-optic endoscope. It is automatically controlled by a servomotor to produce a single two-dimensional image of the entire endometrial cavity, including visualization of lesions. Subsequently, a directed biopsy may be accomplished using the servomotor system and the coordinates of the lesion from the Endometrial Map. The Phase I prototype will incorporate a 360-degree panoramic imaging endoscope, special image-processing software, and full color CCD technology to produce a single integrated Endometrial Map. We will test this system in ex-vivo human uteri and characterize its performance relative to visual inspection of the dissected uterus. If we obtain proof-of-concept of the imaging system, we hope to proceed to Phase II, which will focus on integration of the biopsy apparatus, and testing the device in an animal model and in a clinical study. It is our long-term goal that the device will be used as a minimally invasive tool for accurate identification and directed biopsy of endometrial pathology. PROPOSED COMMERCIAL APPLICATION: This year alone there will be 38,300 new cases of endometrial cancer in women. If the device proves to create a simple method to image the endometrium and direct biopsies, it will have a major impact on the clinical practice of gynecology.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

43 SBIR/STTR records share this UEI (1998–2023). Reported award amounts total $40,867,223. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.